GenomaLab is a healthcare company committed to improving patient outcomes through access to innovative, high-quality pharmaceutical products.

Novazepra® is marketed by GenomaLab Medical LLC, United Arab Emirates, the Marketing Authorization Holder (MAH) responsible for ensuring compliance with applicable regulatory requirements and maintaining the highest standards of quality and pharmacovigilance.

In the Sultanate of Oman, Novazepra® is supported by GenomaLab Healthcare LLC, providing local medical and commercial support to healthcare professionals and patients.

With a growing international presence, Novazepra® is approved and marketed across 28 countries and continues to expand its reach throughout the Middle East and Africa.

Our mission is to improve metabolic health by providing safe, effective, and accessible therapeutic solutions supported by scientific integrity and patient-centered care.